Jane A. Fagerland

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity

Lutz Müller, Robert J. Mauthe, Christopher M. Riley et al. · Regulatory Toxicology and Pharmacology · 2006 · 454 citations

Biochemistry, Drug Resistance, Medicine +10

Astrovirus and Breda virus infections of dome cell epithelium of bovine ileum

G. N. Woode, Joachim Pohlenz, N E Gourley et al. · Journal of Clinical Microbiology · 1984 · 126 citations · Full text

Immunology, Pathology, Education +17

Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds

James M. Trevillyan, X. Grace Chiou, Yung‐Wu Chen et al. · Journal of Biological Chemistry · 2001 · 99 citations · Full text

A quantitation method for mass spectrometry imaging

Stormy L. Koeniger, Nari Talaty, Yanping Luo et al. · Rapid Communications in Mass Spectrometry · 2011 · 92 citations · Full text

Engineering, Clinical Mass Spectrometry, Biological Mass Spectrometry +26

Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes11Abbreviations: MMP, matrix metalloproteinase; MMPI, matrix metalloproteinase inhibitor; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; NBD-PE, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine; and MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; DMSO, dimethylsulfoxide; HPLC, high performance liquid chromatography.

Rebecca J. Gum, Dean Hickman, Jane A. Fagerland et al. · Biochemical Pharmacology · 2001 · 55 citations